VIR (Vir Bio) Net earnings per share (EPS TTM)

Vir Biotechnology, Inc. (VIR) develops universal antibodies for chronic virus therapy, capturing the niche of combating hepatitis B. The rolling YoY earnings per share change confirms market trends, where the value 65.70 reflects current dynamics. Demand is driven by epidemiology rather than economics. Stability is ensured by a substantial cash reserve that offsets research and development costs.
VIR (Vir Biotechnology, Inc.): analytical breakdowns and indicator data

To minimize investment risks, it is necessary to evaluate the rate of change in net income per share over a rolling twelve-month period. By analyzing the current annual growth of EPS TTM, an investor can see the monetization dynamics of the scientific base of Vir Biotechnology, Inc. (VIR), where an upward trend confirms the effectiveness of antibody development and the success of strategic partnerships with global pharma behemoths.